(Q47678860)

4 February 2018

meta-analysis

0 references

title

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials (English)

1 reference

4 February 2018

0 references

5

Alexander Eggermont

1 reference

4 February 2018

Stefan Suciu

6

object named as

Stefan Suciu

1 reference

4 February 2018

author name string

Keith Wheatley

1

1 reference

4 February 2018

Natalie Ives

2

1 reference

4 February 2018

Barry Hancock

3

1 reference

4 February 2018

Martin Gore

4

1 reference

4 February 2018

publication date

1 August 2003

1 reference

4 February 2018

published in

Cancer Treatment Reviews

1 reference

4 February 2018

volume

29

1 reference

4 February 2018

issue

4

1 reference

4 February 2018

page(s)

241-252

1 reference

4 February 2018

Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Adjuvant interferon-alpha for melanoma revisited: news from old and new studies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Interferon alfa-2a for melanoma metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Results of adjuvant interferon study in WHO melanoma programme

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

An update on adjuvant interferon for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900074-4

7 January 2021

10.1016/S0305-7372(03)00074-4

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018